MolDX: Melanoma Risk Stratification Molecular Testing

Molecular diagnostic tests for melanoma risk stratification are covered when the patient has a personal history of melanoma, is non‑metastatic, is undergoing workup or treatment evaluation, and meets staging thresholds (T1b+ or T1a with inadequate microstaging) with a presumed SLNB risk >5%. Coverage also requires that the specific test fall within its intended use and have a Technical Assessment demonstrating clinical validity, clinical utility beyond standard factors, analytical validity, and comparable or superior performance to other covered tests.

"Patient has a personal history of melanoma."

Sign up to see full coverage criteria, indications, and limitations.